Leerink Partners Immuno-Oncology Roundtable.

Pfizer Oncology Presentation
October 1 2015

Pfizer Oncology

Pfizer Oncology

Liz Barrett
President, Pfizer Oncology
October 1 2015

Pfizer Oncology

Forward Looking Statements

Our discussion during this presentation includes forward-looking statements about, among other things, development of Pfizer's products and product candidates and our oncology strategy, including their potential benefits, and expected clinical trial study starts, regulatory submissions, regulatory approvals and product launches that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in our subsequent reports on Form 8-K, all of which are filed with the SEC and available at www.sec.gov and www.pfizer.com. The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements.

Pfizer's Oncology Strategy, Pipeline and Portfolio

Pfizer Oncology: Today and in the Future

Today

Growing Product Line

AROMASIN exemestane tablets | SUTENT capsules sunitinib malate | TORISEL (temsirolimus) Injection | MYLOTARG (gemtuzumab ozogamicin) for IV infusion *(Japan only)*

4 Launches in 4 Years

IBRANCE palbociclib 125 mg capsules | XALKORI CRIZOTINIB | Inlyta axitinib | Bosulif bosutinib 500 mg tablets

PIPELINE

Early-Stage Pipeline

Targeting the Immune System

Immuno-Oncology
- Avelumab (PD-L1)
- 4-1BB
- OX-40
- CCR2
- VIBR

Small Molecules
- Gedatolisib (PI3K/mTor IV)
- Lorlatnib (ALK/ROS1)
- Palbociclib

Targeting the Tumor

Antibody-Drug Conjugates
- Notch 3 ADC
- TROP2 ADC
- PTK-7 ADC
- P-Cadherin (bi-specific)

Growing Late-Stage Portfolio

Palbociclib
- mBC / High-Risk eBC

Axitinib
- mRCC Adj

Avelumab (PD-L1)
- NSCLC

Sunitinib
- RCC Adj

Dacomitinib
- NSCLC

Inotuzumab
- ALL

Crizotinib
- NSCLC 1L (ex-US); NSCLC ROS1

Bosutinib
- CML 1L

Ibrance Brand Vision

PALOMA-1	PALOMA-3	PALOMA-2	PEARL	PENELOPE-B	PALLAS	Additional Trials
1L ER+, HER2- Adv BC	Recurrent ER+, HER2- Adv BC	1L ER+, HER2- Adv BC	Recurrent ER+, HER2- Adv BC	ER+ eBC (High Risk)	ER+ eBC (Stages II-III)	HNSCC, Pancreatic, Other Tumors

KEY:

ADC: Antibody Drug Conjugate
CAR-T: Chimeric Antigen Receptor T-Cell
eBC: Early Breast Cancer
ER+: Estrogen Receptor Positive
HER2: Human Epidermal Growth Factor Receptor-2
HNSCC: Head and Neck Squamos Cell Carcinoma
mAbs: Monoclonal Antibodies
NCEs: New Chemical Entities
NSCLC: Non-Small Cell Lung Cancer
mBC: Metastatic Breast Cancer
MHC: Major Histocompatability Complex
RCC: Renal Cell Carcinoma
TCR: T-Cell Receptor

Targeting the Immune System: A New Front in the War on Cancer



Strategic Approach to Oncology Research



Innovative Modalities Support Strategy and Drive Future of Therapies

NCEs | mAbs | ADCs | Bi-specifics | Vaccines | CAR-T

Pfizer Oncology: An Exciting Road Ahead

- Excellent uptake of Ibrance reaching over 12,000 patients since February 2015 launch
- Our goal is to deliver 1-2 new product launches a year for next 3 years as well as potential indication expansions for Bosuilif, Xalkori and Ibrance
- In addition, we will aim for 7-9 pivotal study starts in 2015 and 3-5 a year for next 3 years
- 5 IO compounds in the clinic in 2015 and the potential to have up to 10 in 2016
- Uniquely positioned in immuno-oncology with breadth of portfolio and combination strategy

Pfizer Oncology

Immuno-Oncology

Chris Boshoff, VP, Early Development, Translational, & Immuno-Oncology

Pfizer Oncology

Pfizer Is Focused on a Multi-Pronged Approach to IO

Advance Focused Single Agent Program

- Accelerated development for target tumors: PD1, PDL1, 41BB
- Enable rapid advancement to combination strategies

Breadth and Depth of Our Portfolio Offers Potential for Several IO Combos

- Pfizer will have five IO agents in development this year: PD-L1, 4-1BB, OX40, CCR2 and VIBR
- Multiple ADCs and range of small molecules for potential combinations
- Anticipated combinations with avelumab in 2015 include: +ALK/ROS; + Inlyta; + 4-1BB

Expand Portfolio Through Acquisitions and/or Collaborations

- Strengthen portfolio, grow scientific expertise; such as CAR-T (Cellectis) and IDO1 (iTEOS)

Pfizer Oncology

Pfizer's Pipeline Targets Multiple Immune Mechanisms



Checkpoint inhibitors
- Anti-PD-L1 avelumab (Ph 3 with Merck KGaA)
- Anti-PD-1 PF-06801591 (IND '15)

Activate T cells
- CD137/4-1BB (Ph 1)
- OX-40 agonist antibody (Ph 1)

Deplete Treg cells
- CCR4 antibody mogamulizumab (Ph 1 with Kyowa Hakko Kirin Pharma)

Abrogate suppression from macrophages & MDSCs
- M-CSF antibody PD-0360324 (Ph 1)
- CCR2 inhibitor PF-04136309 (Ph 1)
- IDO1/TDO2 inhibitors (Preclinical)

Transfer engineered T cells
- Allogeneic CAR-T (Preclinical with Cellectis)

Rational Combinations

Our Immunotherapy Portfolio

Our Kinase Inhibitors



Pfizer Oncology

Avelumab (anti-PD-L1)

Potential to Elicit Antibody -Mediated Cell Cytotoxicity (ADCC)



Key Competitors				
	MedImmune	Roche	Bristol-Myers Squibb	MERCK
	DURVALUMAB	ATEZOLIZUMAB	OPDIVO	KEYTRUDA

Pfizer Oncology

JAVELIN
Clinical Trial Program

- The JAVELIN Clinical Trial Program is assessing the safety and efficacy of Avelumab across multiple tumor types
- >1,000 patients treated as part of multicenter, dose-escalation and parallel-group, dose-expansion phase I trial (NCT01772004; JAVELIN Solid Tumor)
- Avelumab efficacy and safety are being investigated in various tumor types; similar profile to competitors
- Efficiency and effective decision-making in program design and implementation

JAVELIN Solid Tumor: Phase I Study 2015 (EMR 100070-001)

Dose Escalation Phase

Dose Expansion Phase

Completed Efficacy	Signal Detection	Expanded Efficacy
NSCLC 2L	CRC	Ovarian
Gastric Cancer	CRPC	Bladder
mBreast Cancer	Ovarian Cancer	Head and Neck
NSCLC 1L	Melanoma	Gastric 3L
	Bladder	RCC 1L & 2L
	Mesothelioma	
	Adrenocortical	
	RCC	

Pfizer Merck KGaA Darmstadt · Germany

JAVELIN Clinical Development Program Across 15 Tumor Types

- Progress year-to-date represents robust program across more than 15 tumor types and lines of therapy
- By the end of 2015, we plan to initiate up to 6 pivotal studies
- By ASCO 2016, we expect JAVELIN clinical program will include up to 25 trials studying avelumab as single agent and combination therapy
- If successful, first potential commercial launch for avelumab anticipated in 2017 . We expect at least one or more additional launches each year through 2022.



KEY:

- Phase I / IB
- Phase II
- Phase III

Pfizer Merck KGaA Darmstadt · Germany

CD137/4-1BB Mechanism of Action

Urelumab (BMS 663513)

- IgG4; $t_{1/2}$~8-12h; Q3W
- Does not block natural ligand

PF-05082566

- IgG2; $t_{1/2}$ ~ 10h; Q4W
- Ligand binding blocker



Pfizer Oncology

Rituxan + PF-2566
Durable CR in Heavily Pretreated R-refractory FL





Pfizer Oncology

Thank You

Pfizer Oncology